Please upgrade your browser.
The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy.
Michael Lawing, now 67, wasn't much for going to the doctor. Born and raised in Spindale, North Carolina, he always felt so healthy that he didn't see a need.
#GivingTuesday raised a total of $2,620 for kidney cancer research, education, and advocacy. Thanks to all who contributed!
Some potentially good news for all you carnivores out there: A new study shows meat itself might not cause cancer. It could be how you cook it.
Presentation of results from a University of Utah (Huntsman Cancer Institute)-led research study at the 14th International Kidney Cancer Symposium in Miami, Florida, on November 7th, 2015.
Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium
“We are excited to present interim data from the ongoing Phase IIa clinical trial showing that Archexin, in combination with everolimus (Afinitor®), appears to be safe and well tolerated at the doses tested to date.
The clinical development program for avelumab now includes more than 1,400 patients who have been treated across more than 15 tumor types, including breast cancer, gastric/gastro-esophageal (GEJ) cancers, head and neck cancer, Merkel cell carcinoma, melanoma, NSCLC, ovarian cancer, renal cell carcinoma and urothelial (e.g., bladder) cancer.
We aimed to investigate whether expression in the primary tumour of genes involved in the development of BM is associated with outcome in m-ccRCC patients treated with anti-VEGFR-TKIs.
Tumor-specific alternative splicing is implicated in the progression of cancer, including clear-cell renal cell carcinoma (ccRCC).
Clear cell renal cell carcinomas (ccRCCs) display divergent clinical behaviours. Molecular markers might improve risk stratification of ccRCC.
|Powered by NeonCRM|